Replies to post #127723 on Biotech Values

[rkrw]

ALN-RSV01 is for treatment of RSV as opposed to preventing with a vaccine.

[DewDiligence]

ALNY’s phase-2b data for ALN-RSV01 misses primary endpoint on ITT basis, but hits on LOCF and PP calculations:

http://finance.yahoo.com/news/alnylam-announces-top-line-results-100000007.html

The stock is little changed today. Did anyone here listen to the CC?